SCA
ALNY icon

Spearhead Capital Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Spearhead Capital Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,151
Closed -$314K – 103
2022
Q2 		$314K Sell
2,151
-26
-1% -$3.69K 0.05% 118
2022
Q1 		$355K Sell
2,177
-905
-29% -$138K 0.04% 112
2021
Q4 		$523K Buy
3,082
+165
+6% +$30.7K 0.06% 97
2021
Q3 		$551K Buy
2,917
+88
+3% +$16.5K 0.07% 85
2021
Q2 		$480K Buy
2,829
+402
+17% +$58.9K 0.07% 107
2021
Q1 		$343K Buy
2,427
+308
+15% +$46.4K 0.05% 130
2020
Q4 		$275K Buy
2,119
+96
+5% +$12.8K 0.04% 146
2020
Q3 		$295K Buy
2,023
+117
+6% +$16.6K 0.06% 133
2020
Q2 		$282K Buy
+1,906
New +$257K 0.06% 112

Other funds holding ALNY

N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Spearhead Capital Advisors's ALNY Position: Q3 2022 in Review

Spearhead Capital Advisors sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2022, closing a stake of 2,151 shares — an estimated $314K sold.

Spearhead Capital Advisors first reported a position in ALNY in Q2 2020 and held it in 9 quarters. The position peaked at $551K in Q3 2021. 497 funds tracked by Wall St. Rank hold ALNY as of Q3 2022.

  • Spearhead Capital Advisors reported no remaining Alnylam Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Spearhead Capital Advisors sold 2,151 Alnylam Pharmaceuticals shares in Q3 2022, an estimated $314K.
  • Spearhead Capital Advisors first reported a position in Alnylam Pharmaceuticals in Q2 2020 and held it in 9 quarters.
  • Spearhead Capital Advisors's Alnylam Pharmaceuticals position peaked at $551K in Q3 2021.
  • 497 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2022.

Based on Spearhead Capital Advisors's 13F filing for Q3 2022, filed 9 Nov 2022.